Financial Results, Acquisition Agreement, and Investor Meeting - Analyst Notes on Zoetis, Horizon Pharma, Akorn, Furiex and Medicines Co.

NEW YORK, May 16, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Zoetis Inc. (NYSE: ZTS), Horizon Pharma, Inc. (NASDAQ: HZNP), Akorn, Inc. (NASDAQ: AKRX), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) and Medicines Co. (NASDAQ: MDCO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2536-100free.

--
Zoetis Inc. Analyst Notes
On May 6, 2014, Zoetis, Inc. (Zoetis) reported its Q1 2014 financial results with revenues of $1.1 billion, up 0.6% YoY. Net income attributable to Zoetis totaled $155 million or $0.31 per diluted share, compared to $140 million or $0.28 per diluted share in Q1 2013. "We began the year with 4% operational growth in revenue, adjusted net income growing faster than sales, and we remain confident in meeting our financial objectives for the year," said Zoetis CEO Juan Ramón Alaix. "Despite some challenges in the first quarter, we grew sales operationally in three of our regional segments and across all our major species. Our performance in the U.S. and across emerging markets helped offset an operational decline in certain developed markets in Europe and Asia-Pacific." The Company anticipates full-year 2014 revenues to be between $4.65 billion and $4.75 billion and reported diluted EPS to be between $1.15 and $1.21 per share. The full analyst notes on Zoetis are available to download free of charge at:

http://www.analystsreview.com/2536-ZTS-16May2014.pdf

--
Horizon Pharma, Inc. Analyst Notes
On May 9, 2014, Horizon Pharma, Inc. (Horizon Pharma) reported its Q1 2014 financial results with net sales of $51.9 million compared to $8.7 million in Q1 2013. Adjusted EBITDA was $11.0 million compared to $1.1 million in Q1 2013. GAAP net loss was $206.3 million or $3.07 per share, compared to $22.2 million or $0.36 per share in Q1 2013. "2014 is off to a great start with record revenues for the quarter and our first ever non-GAAP quarterly profit," said Timothy P. Walbert, Chairman, President and CEO, Horizon Pharma. "As a result of our outperformance in the quarter and including an expected five months of ACTIMMUNE sales, we have increased our net revenues and adjusted EBITDA guidance for the year." For full year 2014, the Company expects net revenues in the range of $270-$280 million and adjusted EBITDA to be in the range of $80-$90 million. The full analyst notes on Horizon Pharma are available to download free of charge at:

http://www.analystsreview.com/2536-HZNP-16May2014.pdf

--
Akorn, Inc. Analyst Notes
On May 9, 2014, Akorn, Inc. (Akorn) announced that it has entered into a definitive agreement to acquire VPI Holdings Corp., the parent company of privately-held developer and marketer of multi-source prescription pharmaceuticals - VersaPharm Inc. (VersaPharm), for $440 million in cash. Raj Rai, Akorn's CEO commented, "This acquisition is a highly strategic fit with the recently acquired Hi-Tech platform as well as Akorn's focus on niche dosage forms. Our acquisition strategy will have resulted in doubling our revenues and product portfolio in a short period of time. With this acquisition we have further diversified our portfolio. We are also very excited about VersaPharm's robust pipeline that will further accelerate our Company's long-term growth opportunities." The acquisition is expected to add $90-$100 million in Akorn's annual revenues and $0.10 to $0.12 in EPS. Akorn anticipates the closing of the transaction in Q3 2014. The full analyst notes on Akorn are available to download free of charge at:

http://www.analystsreview.com/2536-AKRX-16May2014.pdf

--
Furiex Pharmaceuticals, Inc. Analyst Notes
On May 7, 2014, Furiex Pharmaceuticals, Inc. (Furiex) reported its Q1 2014 financial results with total revenues of $6.4 million compared to $39.3 million in Q1 2013. Net loss was $13.1 million or $1.25 per diluted share, compared to a net income of $9.0 million or $0.82 per diluted share in Q1 2013. Research and development expenses were $14.3 million compared to $25.4 million in Q1 2013. According to the Company, the decrease in research and development expenses was due primarily to the timing and progression of the Phase III clinical trial costs associated with the continued development of eluxadoline. The full analyst notes on Furiex are available to download free of charge at:

http://www.analystsreview.com/2536-FURX-16May2014.pdf

--
Medicines Co. Analyst Notes
On May 8, 2014, The Medicines Company announced that it is hosting a surgery and perioperative care investor and analyst meeting on May 22, 2014, Thursday. The event will be held from 8:30 a.m. to 12:00 noon. The said meeting will take place at the Company's Global Center 1 at 8 Sylvan Way in Parsippany, NJ. The Company informed that the meeting is being hosted to highlight The Medicines Company's second emerging core business of surgery and perioperative care. The full analyst notes on Medicines Co. are available to download free of charge at:

http://www.analystsreview.com/2536-MDCO-16May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED